Halozyme Therapeutics | HALO - Pre Tax Profit


Halozyme Therapeutics reported $180.33M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amarin USD -852K 7.26M Dec/2025
Amgen USD 2.08B 570M Mar/2026
Baxter International USD 362M 368M Jun/2026
Cara Therapeutics USD -6.8M 1.9M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
DBV Technologies USD -47.4M 14.24M Mar/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -114M 21M Jun/2026
MannKind USD -16.37M 4.56M Mar/2026
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
United Therapeutics USD 372.7M 54.4M Jun/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024